MERS-CoV

• Auteur principal: Du, Lanying (auth)
• Autres auteurs: Li, Fang (auth)
• Format: Électronique Chapitre de livre
• Langue: anglais
• Publié: MDPI - Multidisciplinary Digital Publishing Institute 2019
• Sujets: Biology, life sciences; cell-cell fusion; hDPP4; n/a; therapeutics; animal models; HCoV-229E; Drivers; camels; rabbits; SARS-CoV; MERS-CoV; MVA vaccine; transmission; RBD; MERS-CoV nucleocapsid protein; complement; animal model; pseudotyped virus; combination; MERS-coronavirus; peptide; mouse model; spike protein; receptor-binding domain; prevention and treatment; coronaviruses; coronavirus spike glycoprotein; therapeutic antibodies; vaccine platforms; mutation; severe acute respiratory syndrome coronavirus; pathogenesis; fusion inhibitor; Coronavirus; murine CD8+ T cell epitope; lipidomics; authentic virus; correlates of immunity; vaccines; neutralizing monoclonal antibodies; Middle East respiratory syndrome coronavirus; small-molecule inhibitor; Middle East Respiratory Syndrome Virus; DPP4; pyroptosis; cross-neutralization; inflammation; Qatar; spike proteins; One Health; HKU4; nanobodies; mechanism of action; neutralizing antibody; host factors; UHPLC-MS
• Accès en ligne: DOAB: download the publication; DOAB: description of the publication

Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated...